MedTrace Logo

Validation Study of the Korean Version of the EORTC QLQ-HDC29

NCT01208532 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 226

Last updated 2015-04-23

No results posted yet for this study

Summary

The aim of this study is to evaluate the reliability and validity of the Korean version of the European Organization for Research and Treatment of Cancer High-dose Chemotherapy module (EORTC HDC-29).

Conditions

  • Quality of Life After Stem Cell Transplantation

Sponsors & Collaborators

  • Seoul National University Hospital

    lead OTHER

Principal Investigators

  • Sung-Soo Yoon, MD, PhD · Seoul National University Hospital

  • Jung Mi Oh, Pharm.D. · College of Pharmacy, Seoul National University

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-09-30
Primary Completion
2013-12-31
Completion
2013-12-31

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01208532 on ClinicalTrials.gov